

AMENDMENTS TO THE CLAIMS

1-12. (Canceled)

13. (Currently amended) A method for enhancing glucose uptake into warm-blooded animal cells, comprising administering to a warm-blooded animal in need thereof an effective amount of pravastatin or pharmacologically acceptable salts or esters thereof sufficient to enhance glucose uptake into warm-blooded animal cells, wherein glucose uptake does not include glucose transport.

14. (Withdrawn-Currently amended) A method for enhancing glucose uptake into warm-blooded animal cells in the presence of insulin, comprising administering to a warm-blooded animal in need thereof an effective amount of pravastatin or pharmacologically acceptable salts or esters thereof sufficient to enhance glucose uptake into warm-blooded animal cells, wherein glucose uptake does not include glucose transport.

15-18. (Canceled)

19. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of pravastatin or pharmacologically acceptable salts or esters thereof sufficient to enhance glucose uptake into warm-blooded animal cells, wherein glucose uptake does not include glucose transport.

20. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or

prophylaxis of diabetes complications in a warm-blooded animal, caused by insulin resistance syndrome, comprising administering to a warm-blooded animal in need of such treatment an effective amount of pravastatin or pharmacologically acceptable salts or esters thereof sufficient to enhance glucose uptake into warm-blooded animal cells, wherein glucose uptake does not include glucose transport.

21. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of pravastatin or pharmacologically acceptable salts or esters thereof sufficient to enhance glucose uptake into warm-blooded animal cells, wherein glucose uptake does not include glucose transport.

22. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, caused by insulin resistance syndrome, comprising administering to a warm-blooded animal in need of such treatment an effective amount of pravastatin or pharmacologically acceptable salts or esters thereof sufficient to enhance glucose uptake into warm-blooded animal cells, wherein glucose uptake does not include glucose transport.

23-24. (Canceled)

25. (Previously presented) A method according to claim 13, wherein the warm-blooded animal is a human.

26. (Withdrawn) A method according to any one of claims 19, 20, 21, or 22, wherein the diabetes complication is retinopathy, nephropathy, neuropathy, cataract disease, or coronary artery disease.

27-30. (Canceled)

31. (Previously presented) A method according to claim 13, wherein administering an effective amount of pravastatin or pharmacologically acceptable salts or esters thereof comprises administering pravastatin or pharmacologically acceptable salts or esters thereof in the presence of insulin.

32. (Canceled)

33. (Previously presented) A method according to claim 13, further comprising administering an effective amount of a second HMG-CoA reductase inhibitor selected from the group consisting of lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin, and rosuvastatin.

34. (Canceled)

35. (Previously presented) A method according to claim 31, further comprising administering an effective amount of a second HMG-CoA reductase inhibitor selected from the group consisting of lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin, and rosuvastatin.

36. (New) A method for enhancing glucose uptake into warm-blooded animal adipocytes, comprising administering to a warm-blooded animal in need thereof an effective

amount of pravastatin or pharmacologically acceptable salts or esters thereof sufficient to enhance glucose uptake into warm-blooded animal adipocytes.

37. (New) The method of Claim 36, wherein the glucose uptake occurs from the interstitial fluid of peripheral adipose tissues.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100